Neil Petry

About

As Director of the Duke Medical Center Radiopharmacy, which is permitted by the North Carolina Board of Pharmacy, I am responsible for the procurement, formulation, quality control testing, and dispensing of all radiopharmaceuticals for diagnostic, therapeutic, and clinical research use at Duke University Hospital. Service accomplishments included providing all radiopharmaceuticals used for routine patient care at Duke Medical Center. In addition, the Radiopharmacy service participates in a wide variety of clinical research protocols undertaken by Duke investigators either by consultation regarding pharmaceutical formulation of research compounds or actually performing these formulations as a specialized service. Radiopharmacy service operations are conducted in a state of the art USP <797> and <825> compliant clean room environment. This lab space is specifically designed to satisfy a wide variety of sterile radiopharmaceutical compounding needs for both routine patient care and clinical research. My general research interests focus on the development and clinical evaluation of diagnostic and therapeutic radiopharmaceuticals (radiotheranostics) for patient care. Specific research interests focus on the clinical applications of 1.) Carbon C-11, Nitrogen N-13, Oxygen 0-15 and Fluorine F-18 labeled radiopharmaceuticals for Positron Emission Tomography (PET) based molecular imaging and 2.) Radiolabeling antibodies, small molecules and peptides with diagnostic and therapeutic radionuclides for radiotheranostics of human cancers. Therapeutic radionuclide experience includes Astatine-211, Actinium-225, Iodine-131, Lutetium-177, Radium-223 and other alpha and beta emitters. I am highly experienced and knowledgeable concerning the regulations which govern the development of and FDA approval of radiopharmaceuticals for radiotheranostic applications in medicine. Finally, I am interested in the development of radiopharmaceutical care models in nuclear medicine to optimize the patient's health related quality of life, and achieve positive clinical outcomes, within realistic economic expenditures.

Education

Publications